Precision Therapeutics Inc (NASDAQ:POAI) Sees Significant Increase in Short Interest
Precision Therapeutics Inc (NASDAQ:POAI) saw a large increase in short interest in the month of November. As of November 29th, there was short interest totalling 69,900 shares, an increase of 12.7% from the November 14th total of 62,000 shares. Based on an average daily volume of 24,700 shares, the short-interest ratio is presently 2.8 days. Approximately 2.2% of the company’s shares are sold short.
Separately, ValuEngine upgraded Precision Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, December 3rd.
NASDAQ:POAI traded up $0.16 during mid-day trading on Friday, reaching $2.88. 15,048 shares of the company’s stock traded hands, compared to its average volume of 39,812. Precision Therapeutics has a 12-month low of $2.35 and a 12-month high of $11.50. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.10 and a quick ratio of 0.08. The firm’s 50 day moving average is $3.29.
Precision Therapeutics Company Profile
Predictive Oncology Inc provides various healthcare products and services primarily in the United States. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers the STREAMWAY Fluid Waste Management system that suctions surgical waste fluid from the patient using standard surgical tubing; and disposables.
Featured Story: How Short Selling Works
Receive News & Ratings for Precision Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.